Trained Immunity in Tissue Repair: Mechanisms, Clinical Implications, and Therapeutic Horizons

Abstract

Trained immunity, a concept describing the memory-like functional reprogramming of innate immune cells, has emerged as a pivotal factor in orchestrating tissue repair. This review explores the cellular and molecular mechanisms underlying trained immunity in the context of tissue injury, examines its clinical relevance, and discusses the translational potential of targeting trained innate responses for optimizing tissue regeneration and healing. Recent evidence from experimental and clinical studies is synthesized, with a focus on the epidemiological burden of impaired tissue repair, the pathophysiological role of innate immune training, associated risk factors, clinical features, diagnostic considerations, management strategies, and current guideline recommendations. Advances in immunomodulatory therapies and future research directions are highlighted to inform clinical practice and innovative therapeutic development.

Introduction

The traditional paradigm of immunological memory has long been confined to adaptive immunity, but recent discoveries have established that innate immune cells, such as monocytes, macrophages, and natural killer (NK) cells, can also acquire a form of memory referred to as trained immunity. This phenomenon involves epigenetic, metabolic, and functional reprogramming following certain stimuli, resulting in enhanced or altered responses to subsequent challenges. In the context of tissue injury, trained immunity modulates the balance between inflammation and repair, influencing outcomes in a wide range of clinical scenarios, from wound healing to post-surgical recovery and organ regeneration. Understanding the nuances of this process is critical for clinicians seeking to optimize tissue repair and minimize complications in diverse patient populations.

Epidemiology / Disease Burden

Tissue injury and impaired repair processes constitute a substantial burden on global healthcare systems, with chronic wounds alone affecting over 40 million patients worldwide. Non-healing wounds, delayed fracture repair, and maladaptive scar formation contribute to prolonged morbidity, increased hospitalization, and significant healthcare costs. The epidemiological impact is amplified in aging populations, patients with diabetes, immunosuppression, and those undergoing major surgical interventions. Mounting evidence suggests that dysregulated innate immune responses, including aberrant trained immunity, are central to the pathogenesis of impaired tissue repair, underscoring the need for deeper mechanistic insights and targeted interventions.

Pathophysiology

Trained immunity is characterized by sustained changes in innate immune cell function, driven by epigenetic modifications such as histone methylation and acetylation, metabolic reprogramming towards glycolysis and oxidative phosphorylation, and altered cytokine production. Upon exposure to certain pathogens, damage-associated molecular patterns (DAMPs), or pharmacological agents, innate cells undergo a priming phase, leading to heightened responsiveness upon re-challenge. In tissue repair, this can enhance the removal of cellular debris and pathogens, promote angiogenesis, and facilitate matrix remodeling. However, excessive or maladaptive training may contribute to chronic inflammation, fibrosis, and impaired regeneration. Key molecular players include NOD-like receptors, IL-1β/IL-6 signaling, and metabolic sensors such as mTOR and HIF-1α, which collectively orchestrate the reparative or pathological outcomes of trained immunity.

Risk Factors

The induction and effects of trained immunity in tissue repair are modulated by a range of risk factors. Advanced age, diabetes mellitus, obesity, chronic infections, and repeated tissue injury can predispose individuals to aberrant immune training. Environmental exposures—such as prior infections, vaccinations (e.g., BCG), and certain pharmacotherapies—can also influence the functional state of innate immune cells. Genetic predispositions, including polymorphisms in pattern recognition receptors or cytokine genes, further modulate susceptibility to maladaptive trained responses. Understanding these risk factors enables stratification of patients at higher risk for impaired healing and informs personalized management strategies.

Clinical Features

Clinically, aberrations in trained immunity may manifest as delayed wound healing, persistent inflammation at injury sites, exaggerated scar tissue formation, or poor integration of grafts and implants. Patients may present with chronic non-healing ulcers, recalcitrant surgical wounds, or excessive fibrosis in organs such as the liver, lungs, or heart. Systemic features, such as low-grade inflammation or immune dysregulation, may be evident in severe or widespread cases. Recognition of these features is essential for early diagnosis and targeted intervention.

Diagnosis

Diagnosis of impaired tissue repair influenced by trained immunity relies on a combination of clinical assessment and laboratory investigations. Biomarkers of innate immune activation—such as elevated cytokines (IL-1β, TNF-α), increased monocyte/macrophage counts, and specific epigenetic signatures—may provide supportive evidence. Advanced imaging modalities can evaluate tissue inflammation, vascularization, and matrix remodeling. Experimental approaches, including transcriptomic and metabolomic profiling of tissue or blood samples, are being explored to identify specific trained immunity signatures for clinical application. Integrating these diagnostic tools with clinical context is key for comprehensive assessment.

Treatment & Management

Management strategies for optimizing tissue repair in the context of trained immunity include both conventional and emerging approaches. Standard care involves meticulous wound management, infection control, and modulation of systemic risk factors such as glycemic control and nutritional support. Immunomodulatory therapies—such as corticosteroids, biologics targeting pro-inflammatory cytokines, and agents modulating epigenetic or metabolic pathways—are under investigation for their potential to recalibrate maladaptive trained responses. Personalized approaches based on risk stratification and biomarker profiling hold promise for improving outcomes in high-risk patient cohorts.

Recent Advances / Emerging Therapies

Recent advances in the field have highlighted the therapeutic potential of modulating trained immunity for tissue repair. Agents such as β-glucans, BCG vaccine derivatives, and small molecule inhibitors targeting metabolic and epigenetic regulators are being evaluated in preclinical and early-phase clinical studies. Cell-based therapies, including adoptive transfer of reprogrammed macrophages or mesenchymal stem cells, are also being explored for their reparative and immunomodulatory properties. Omics-driven approaches are enabling the identification of novel targets and biomarkers, paving the way for precision immunotherapy in tissue repair. Integration of these innovations into clinical practice will require rigorous validation and multidisciplinary collaboration.

Guideline Recommendations

Current clinical guidelines for tissue repair and wound management emphasize the importance of early intervention, risk factor modification, and evidence-based use of immunomodulatory therapies. While specific recommendations regarding trained immunity are still evolving, expert consensus supports the integration of biomarker-driven approaches for patient stratification and monitoring. Ongoing guideline updates are anticipated as further evidence emerges on the role of trained immunity in clinical outcomes and therapeutic responsiveness.

Conclusion

The recognition of trained immunity as a critical regulator of tissue repair represents a paradigm shift in our understanding of innate immune function and its clinical implications. Advances in mechanistic insight, diagnostic capabilities, and therapeutic interventions are poised to transform the management of tissue injury and impaired healing. Continued interdisciplinary research and evidence-based practice will be essential to fully harness the potential of trained immunity in optimizing patient outcomes and advancing regenerative medicine.